Literature DB >> 12646684

PR interval and the response to enzyme-replacement therapy for Fabry's disease.

Stephen Waldek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12646684     DOI： 10.1056/NEJM200303203481224

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.

Authors:  Jami C Levine; Priya S Kishnani; Y T Chen; J Rene Herlong; Jennifer S Li
Journal:  Pediatr Cardiol       Date:  2008-07-26       Impact factor: 1.655

Review 2.  Enzyme replacement and enhancement therapies for lysosomal diseases.

Authors:  R J Desnick
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

3.  Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

Authors:  William R Wilcox; Maryam Banikazemi; Nathalie Guffon; Stephen Waldek; Philip Lee; Gabor E Linthorst; Robert J Desnick; Dominique P Germain
Journal:  Am J Hum Genet       Date:  2004-05-20       Impact factor: 11.025

Review 4.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

5.  Cardiac electrophysiology in mice: a matter of size.

Authors:  Sven Kaese; Sander Verheule
Journal:  Front Physiol       Date:  2012-09-05       Impact factor: 4.566

Review 6.  Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.

Authors:  R P Morrissey; K J Philip; E R Schwarz
Journal:  Cardiovasc J Afr       Date:  2011 Jan-Feb       Impact factor: 1.167

7.  [Fabry disease: about an uncommon case].

Authors:  Hamid Jallal; Ali Khatori; Laila Bendriss
Journal:  Pan Afr Med J       Date:  2017-12-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.